<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec id="j_jccm-2022-0006_s_006">
<h3>Introduction</h3>
<p>Invasive candidiasis (IC) in critically ill patients is a serious infection with high rate of mortality. As an empirical therapy, like antibiotics, the use of antifungals is not common in intensive care units (ICUs) worldwide. The empirical use of echinocandins including anidulafungin is a recent trend.</p></sec>
<sec id="j_jccm-2022-0006_s_007">
<h3>Aim of the study</h3>
<p>The objective of this study was to assess the impact of empirical anidulafungin in the development of invasive candidiasis in critically ill patients in ICU.</p></sec>
<sec id="j_jccm-2022-0006_s_008">
<h3>Methods</h3>
<p>This retrospective case-control study was conducted on 149 patients with sepsis with/without septic shock and bacterial pneumonia. All the patients were divided into two groups. The ‘control group’ termed as ‘NEAT group’ received no empirical anidulafungin therapy and the ‘treated group’ termed as ‘EAT group’ received empirical anidulafungin therapy in early hospitalization hours.</p></sec>
<sec id="j_jccm-2022-0006_s_009">
<h3>Results</h3>
<p>Seventy-two and 77 patients were divided into the control and the treated group, respectively. Patients in EAT group showed less incidences of IC (5.19%) than that of the NEAT group (29.17%) (p = 0.001). Here, the relative risk (RR) was 0.175 (95% CI, 0.064-0.493) and the risk difference (RD) rate was 24% (95% CI, 12.36%-35.58%). The 30-day all-cause mortality rate in NEAT group was higher (19.44%) than that of in EAT group (10.39%) (p = 0.04). Within the first 10-ICU-day, patients in the EAT group left ICU in higher rate (62.34%) than that in the NEAT group (54.17%).</p></sec>
<sec id="j_jccm-2022-0006_s_010">
<h3>Conclusion</h3>
<p>Early empirical anidulafungin within 6 h of ICU admission reduced the risk of invasive candidiasis, 30-day all-cause mortality rate and increased ICU leaving rate within 10-day of ICU admission in critically ill patients.</p>
</sec>
</abstract>

Introduction
Invasive candidiasis (IC) in critically ill patients is a serious infection with high rate of mortality. As an empirical therapy, like antibiotics, the use of antifungals is not common in intensive care units (ICUs) worldwide. The empirical use of echinocandins including anidulafungin is a recent trend.

Aim of the study
The objective of this study was to assess the impact of empirical anidulafungin in the development of invasive candidiasis in critically ill patients in ICU.

Methods
This retrospective case-control study was conducted on 149 patients with sepsis with/without septic shock and bacterial pneumonia. All the patients were divided into two groups. The ‘control group’ termed as ‘NEAT group’ received no empirical anidulafungin therapy and the ‘treated group’ termed as ‘EAT group’ received empirical anidulafungin therapy in early hospitalization hours.

Results
Seventy-two and 77 patients were divided into the control and the treated group, respectively. Patients in EAT group showed less incidences of IC (5.19%) than that of the NEAT group (29.17%) (p = 0.001). Here, the relative risk (RR) was 0.175 (95% CI, 0.064-0.493) and the risk difference (RD) rate was 24% (95% CI, 12.36%-35.58%). The 30-day all-cause mortality rate in NEAT group was higher (19.44%) than that of in EAT group (10.39%) (p = 0.04). Within the first 10-ICU-day, patients in the EAT group left ICU in higher rate (62.34%) than that in the NEAT group (54.17%).

Conclusion
Early empirical anidulafungin within 6 h of ICU admission reduced the risk of invasive candidiasis, 30-day all-cause mortality rate and increased ICU leaving rate within 10-day of ICU admission in critically ill patients.

Early Empirical Anidulafungin Reduces the Prevalence of Invasive Candidiasis in Critically Ill Patients: A Case-control Study

The Journal of Critical Care Medicine

This work is licensed under the Creative Commons Attribution 4.0 International License.

Introduction
Invasive candidiasis (IC) in critically ill patients is a serious infection with high rate of mortality. As an empirical therapy, like...

Early Empirical Anidulafungin Reduces the Prevalence of Invasive Candidiasis in Critically Ill Patients: A Case-control Study

Article Category: Research Article

Published Online: May 12, 2022

Page range: 89 - 99

Received: Jan 13, 2022

Accepted: Apr 06, 2022

DOI: https://doi.org/10.2478/jccm-2022-0006

Keywords
anidulafungin, critically ill patient, invasive candidiasis, Candida pneumonia, Candida urinary tract infection

© 2022 Md Jahidul Hasan, Sharmind Neelotpol, Raihan Rabbani, published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Early Empirical Anidulafungin Reduces the Prevalence of Invasive Candidiasis in Critically Ill Patients: A Case-control Study

Article Category: Research Article

Published Online: May 12, 2022

Page range: 89 - 99

Received: Jan 13, 2022

Accepted: Apr 06, 2022

DOI: https://doi.org/10.2478/jccm-2022-0006

Keywordsanidulafungin, critically ill patient, invasive candidiasis, Candida pneumonia, Candida urinary tract infection

© 2022 Md Jahidul Hasan, Sharmind Neelotpol, Raihan Rabbani, published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Keywords
anidulafungin, critically ill patient, invasive candidiasis, Candida pneumonia, Candida urinary tract infection